Dodecane

Dodecane

SCHEMBL4233135

CCCCCCCCCCCC.OCC(O)CO

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.60
LMNA P02545 6/20 0.56
ALDH1A1 P00352 2/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
TSHR P16473 2/20 0.53
HSD17B10 Q99714 1/20 0.53
KDM4E B2RXH2 2/20 0.52
DUSP3 P51452 1/20 0.52
CYP2D6 P10635 2/20 0.50
SPHK1 Q9NYA1 1/20 0.50
GMNN O75496 1/20 0.50
POLB P06746 1/20 0.50
THPO P40225 1/20 0.50
MTOR P42345 1/20 0.50
BLM P54132 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nonane SCHEMBL11639112 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Decane SCHEMBL27510417 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Dodecane SCHEMBL16652552 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Hexadecane SCHEMBL4476638 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Octane SCHEMBL2362539 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Heptane SCHEMBL8025180 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Octane SCHEMBL3691269 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Glycerin SCHEMBL28505432 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Octane SCHEMBL2522455 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A
Tetradecane SCHEMBL27410093 1.00 USP2 (0.60) USP2LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113905796-A Novel solvents for extracting, dissolving and/or formulating volatile and non-volatile compounds of interest in nutrition and animal health, method for the production and use thereof 艾迪福科技有限公司 2022-01-07 CN disclosed
CN-109496148-B Skin whitening cosmetic composition containing glyceryl laurate 明进新科技股份公司 2021-09-17 CN disclosed
US-9244372-B2 Electrostatic charge image developing toner, electrostatic charge image developer, and toner cartridge FUJI XEROX CO., LTD. (JP) 2016-01-26 US disclosed
US-20150111139-A1 ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, ELECTROSTATIC CHARGE IMAGE DEVELOPER, AND TONER CARTRIDGE FUJI XEROX CO., LTD. (JP) 2015-04-23 US disclosed
EP-1786381-B1 ANTI-BACTERIAL COMPOUNDS BEIERSDORF AG (DE) 2014-12-03 EP disclosed
CN-101018538-B Antibacterial compounds GIVAUDAN SA 2011-05-04 CN disclosed
US-20090022764-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2009-01-22 US disclosed
US-7459581-B2 Anti-bacterial compounds GIVAUDAN S.A. (CH) 2008-12-02 US disclosed
US-20080070985-A1 Anti-Bacterial Compounds BEIERSDORF AG (DE) 2008-03-20 US disclosed
US-20070276045-A1 Anti-Bacterial Compounds GIVAUDAN S.A. (CH) 2007-11-29 US disclosed
CN-101018538-A Antibacterial compounds GIVAUDAN SA (CH) 2007-08-15 CN disclosed
EP-1788871-A1 ROMP POLYMER PARTICLES COMPRISING ACTIVE INGREDIENTS Givaudan SA (CH) 2007-05-30 EP disclosed
EP-1786756-A1 ANTI-BACTERIAL COMPOUNDS Givaudan SA (CH) 2007-05-23 EP disclosed
EP-1786381-A1 ANTI-BACTERIAL COMPOUNDS Givaudan SA (CH) 2007-05-23 EP disclosed
WO-2006026875-A1 ANTI-BACTERIAL COMPOUNDS GIVAUDAN SA (CH) 2006-03-16 WO disclosed
WO-2006026876-A1 ANTI-BACTERIAL COMPOUNDS GIVAUDAN SA (CH) 2006-03-16 WO disclosed
WO-2006024184-A1 ROMP POLYMER PARTICLES COMPRISING ACTIVE INGREDIENTS GIVAUDAN SA (CH) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070985-A1 Anti-Bacterial Compounds H1-0, H1-3, LBR USP2 4223/4885LMNA 214/4885ALDH1A1 1825/4885
US-20090022764-A1 ORGANIC COMPOUNDS EXOSC9, EXOSC4, CYP1A1 USP2 754/4885LMNA 4050/4885ALDH1A1 544/4885
US-20070276045-A1 Anti-Bacterial Compounds SPOUT1, FASN, CYP8B1 USP2 3909/4885LMNA 1116/4885ALDH1A1 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.